LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib
A phase 3 trial of Ceritinib, Pemetrexed and Docetaxel in Non-small-cell lung cancer, run by Novartis Pharmaceuticals, completed.
Overview
LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib is a phase 3 interventional study registered as NCT01828112 by Novartis Pharmaceuticals, with 231 participants recorded, started 2013-06-28 and reaching its primary completion in 2016-01-26. Interventions recorded: Ceritinib, Pemetrexed, Docetaxel. Conditions recorded: Non-Small Cell Lung Cancer.
Linked to the drug Ceritinib because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialLDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer
Shares Ceritinib, Pemetrexed, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
Shares Docetaxel, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
Shares Pemetrexed, Non-small-cell lung cancer and the tag pipeline.
- TrialA Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
Shares Pemetrexed, Docetaxel and the tag pipeline.
- TrialSAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients
Shares Docetaxel, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
Shares Pemetrexed, Docetaxel, Non-small-cell lung cancer and the tag pipeline.
- TrialA Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
Shares Pemetrexed, Docetaxel and the tag pipeline.
- TrialA Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients
Shares Pemetrexed, Non-small-cell lung cancer and the tag pipeline.